Accessibility Menu
Bio Essence logo

Bio Essence(OTC) BIOE

Market Cap$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-46%
5 YearN/A
1 Year+146%
1 Month-1%
$0.27
+48.6%
+0.09Today
Bio Essence last closing stock price
MetricPriceDate
Last closeUSD 0.272026-06-23
Bio Essence stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7.05%USD 0.252026-06-05
1 month-1.33%USD 0.272026-05-20
3 month+181.56%USD 0.102026-03-25
Year to date+350.5%USD 0.062025-12-29
1 year+145.73%USD 0.112025-06-18
3 year-47%USD 0.512023-06-20
Since inception-45.94%USD 0.502022-12-01

Bio Essence Financials at a Glance

Market Cap

$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.38M

Net Income (TTM)

$1.31M

EPS (TTM)

$0.03

P/E Ratio

8.04

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.27

Volume

1,000

Open

$0.27

Previous Close

$0.27

Daily Range

$0.27 - $0.27

52-Week Range

$0.05 - $0.52

Estimated Earnings Date

Aug 14, 2026

BIOE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio Essence

Bio Essence makes herbal supplements for health professionals and consumers. Its products help with daily nutrition and wellness needs. The company also manufactures supplements for other brands and clinics.

What’s in the Bottle? (Products and Services)

  • Herbal Supplements: Granules, capsules, pills, and tablets for health practitioners and consumers (0% of Q2 2025 revenue).
  • Manufacture Service (OEM): Produces supplements for other brands and clinics; 100% of Q2 2025 revenue.
  • Custom Formulation: Develops special supplement blends for healthcare professionals.
  • Distribution: Supplies health supplement products to practitioners and businesses.

Growth Spurts and Strategic Shifts

  • Sold manufacturing subsidiary in December 2023 and distribution subsidiary in March 2024.
  • Shifted to an outsourced manufacturing model after 2024 divestitures.
  • Focused on expanding OEM services and exploring new business opportunities in 2025.
  • Management is seeking additional funding through private or public offerings.

Why Bio Essence Stands Out (Without the Hype)

Bio Essence operates with a lean team and outsources production, allowing flexibility. Its business depends on a few large customers and vendors, increasing risk. The company focuses on custom supplement manufacturing for health professionals, not direct consumer sales.

Five Things You Need to Know

  • Q2 2025 revenue was $259,123, up 521.5% from Q2 2024.
  • Gross profit margin reached 65.1% in Q2 2025, up from 70% in Q2 2024.
  • Net income was $59,864 in Q2 2025, compared to a $215,678 loss in Q2 2024.
  • Two customers made up 92.1% of sales in the first half of 2025.
  • No cash on hand as of June 30, 2025; relies on shareholder loans.

Bottom Line

Bio Essence has shifted from in-house production to outsourced manufacturing and OEM services. The company remains small, focused, and highly dependent on a few key relationships.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

4

CEO

Yin Yan, MBA

Website

www.bioessencecorp.com

Headquarters

Irvine, CA 92618, US

BIOE Financials

Key Financial Metrics (TTM)

Gross Margin

72.70%

Operating Margin

55.60%

Net Income Margin

55.02%

Return on Equity

-53.81%

Return on Capital

N/A

Return on Assets

165.69%

Earnings Yield

12.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

46.81M

Volume

1.00K

Avg. Volume

898.258

Financials (TTM)

Gross Profit

$1.73M

Operating Income

$1.32M

EBITDA

$1.32M

Operating Cash Flow

$1.18M

Capital Expenditure

$0.00

Free Cash Flow

$1.18M

Cash & ST Invst.

$36.18K

Total Debt

$1.57M

Bio Essence Performance Analysis

Bio Essence annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 621,590-30.0%
20232023-12-31USD 0N/A
20242024-12-31USD 323,940N/A
20252025-12-31USD 1,897,566485.8%
Bio Essence sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301067.8%
Q32025-09-30-47.2%
Q42025-12-31981.5%
Q12026-03-31-66.2%
Bio Essence annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.0225.0%
20232023-12-31USD -0.0324.9%
20242024-12-31USD -0.0445.1%
20252025-12-31USD 0.02N/A
Bio Essence sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30129.6%
Q32025-09-30-81.3%
Q42025-12-318933.3%
Q12026-03-31-83.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$500.54K

+2155.8%

Gross Profit

$319.35K

+1451.2%

Gross Margin

63.80%

N/A

Market Cap

$12.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.16M

N/A

Employees

4

N/A

Net Income

$205.37K

+199.8%

EBITDA

$215.80K

+205.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$36.18K

N/A

Total Debt

$1.57M

-42.9%

Accounts Receivable

$380.49K

+85.2%

Inventory

$0.00

N/A

Long Term Debt

$55.68K

-81.6%

Short Term Debt

$1.51M

-38.1%

Return on Assets

1.66%

N/A

Return on Invested Capital

-96.29%

N/A

Free Cash Flow

-$411.97K

-1480.3%

Operating Cash Flow

-$411.97K

-1480.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RVVTFRevive Therapeutics Ltd.
$0.02+1.11%
RAFARafarma Pharmaceuticals, Inc.
$0.04+28.36%
LVVVLiveWire Ergogenics, Inc.
$0.00+0.00%
LMLLFPharmadrug Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About BIOE

What is the current price of Bio Essence?

Bio Essence is trading at $0.27 per share.

What is the 52-week range for Bio Essence?

Over the past 52 weeks, Bio Essence has traded between $0.05 and $0.52.

How much debt does Bio Essence have?

As of the most recent reporting period, Bio Essence reported total debt of $1.57M.

How much cash does Bio Essence have on hand?

Bio Essence reported $36.18K in cash and cash equivalents in its most recent financial results.

What is Bio Essence’s dividend yield?

Bio Essence does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services